Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid‐associated thrombocytopenia
Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid‐associated thrombocytopenia
复制标题
DOI：
10.1111/jcpt.13747
复制
发表时间：
2022-07
影响因子：
2
通讯作者：
Tetsushu Onita;N. Ishihara;Amika Ikebuchi;Takahisa Yano;N. Nishimura;Hiroki Tamaki;K. Ikawa;N. Morikawa;K. Naora
中科院分区：
文献类型：
--
作者：
Tetsushu Onita;N. Ishihara;Amika Ikebuchi;Takahisa Yano;N. Nishimura;Hiroki Tamaki;K. Ikawa;N. Morikawa;K. Naora
利奈唑胺（LZD）可能引起血小板减少症，这可能导致治疗中止。在本研究中，基于来自日本人群中两个先前发表的模型的群体药代动力学（PK）参数估计血LZD谷浓度，以确定血小板减少症风险较低时达到目标谷值的比率，并阐明其与血小板减少症发作的关系。
Linezolid (LZD) may cause thrombocytopenia, which can result in discontinuation of treatment. In this study, the blood LZD trough concentration was estimated based on population pharmacokinetic (PK) parameters derived from two previously published models in the Japanese population to determine the rate of achieving the target trough value when the risk of thrombocytopenia is low and to clarify its relationship with the onset of thrombocytopenia.